公开(公告)号：US20050069531A1

公开(公告)日：2005-03-31

申请号：US10987483

申请日：2004-11-12

申请人： Hampar Karageozian ,  Vicken Karageozian ,  Maria Kenney ,  Jose Flores ,  Gabriel Carpio Aragon ,  Anthony Nesburn

发明人： Hampar Karageozian ,  Vicken Karageozian ,  Maria Kenney ,  Jose Flores ,  Gabriel Carpio Aragon ,  Anthony Nesburn

IPC分类号： A61K38/46 ,  A61K38/47 ,  A61K38/51

CPC分类号： A61K38/47 ,  Y10S514/912

摘要： An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.

摘要翻译： 提供了一种用于治疗哺乳动物眼睛眼部疾病的酶法。 通过给予一定量的透明质酸酶来有效地液化治疗眼睛的玻璃体液而不会对眼睛造成毒性损伤来实现预防新生血管形成和对视网膜毒性玻璃体的清除率的提高。 玻璃体液的液化增加了玻璃体腔液体的交换速度。 这种交换的增加消除了那些存在导致眼科和视网膜损伤的材料和条件。

公开(公告)号：US20060034822A1

公开(公告)日：2006-02-16

申请号：US11204636

申请日：2005-08-15

申请人： Hampar Karageozian ,  Vicken Karageozian ,  Maria Kenney ,  Jose Gutierrez Flores ,  Gabriel Carpio Aragon ,  Anthony Nesburn

发明人： Hampar Karageozian ,  Vicken Karageozian ,  Maria Kenney ,  Jose Gutierrez Flores ,  Gabriel Carpio Aragon ,  Anthony Nesburn

IPC分类号： A61K38/47 ,  A61K38/46 ,  A61K38/48

CPC分类号： A61K38/47 ,  A61K31/7016 ,  Y10S514/912 ,  A61K2300/00

摘要： A thimerosal-free hyaluronidase preparation wherein the preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,000 MW. Also disclosed is a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of the eye, said method comprising the step of contacting at least one hemorrhage-clearing enzyme (e.g., a β-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase or protein kinase) with the vitreous humor in an amount which is effective to cause accelerated clearance of blood therefrom.

摘要翻译： 不含硫柳汞的透明质酸酶制剂，其中优选的透明质酸酶酶的分子量分数低于40,000MW，在60-70,000MW和高于100,000MW之间。 还公开了一种用于加速来自眼睛玻璃体液的出血血清除的方法，所述方法包括使至少一种出血清除酶（例如，β-葡糖醛酸糖苷酶，基质金属蛋白酶，软骨素酶，软骨素硫酸酯酶或 蛋白激酶），其玻璃体液的量可以有效地引起血液的快速清除。

公开(公告)号：US06537545B1

公开(公告)日：2003-03-25

申请号：US09656849

申请日：2000-09-07

申请人： Hamper Karageozian ,  John Y. Park ,  Vicken Karageozian ,  Phillip Baker ,  Anthony Nesburn

发明人： Hamper Karageozian ,  John Y. Park ,  Vicken Karageozian ,  Phillip Baker ,  Anthony Nesburn

IPC分类号： A61K3844

CPC分类号： G02C7/047 ,  A61F2/147 ,  A61F9/0017 ,  A61F9/013 ,  A61K9/0048 ,  A61L27/50 ,  A61L2430/16

摘要： An Enzyme Orthokeratology method is provided for correcting refractive errors in the eye of a subject mammal. Accelerating reshaping of the cornea is accomplished by administering a corneal hardening amount of a corneal hardening agent to the eye of the subject. Reformation is accomplished under the influence of a rigid contact lens or a series of lenses having a concave curvature that will correct a refractive error. The cornea rapidly reshapes its convex curvature to the concave curvature of the contact lens, rendering the eye emmetropic. The cornea is permitted to “harden” to retain the new emmetropic shape. After “hardening” has occurred, the lens rendering the eye emmetropic is removed.

摘要翻译： 提供了一种用于校正受试哺乳动物眼睛中的屈光不正的酶角膜矫正方法。 通过将角膜硬化量的角膜硬化剂施用于受试者的眼睛来实现加速角膜整形。 在刚性隐形眼镜或具有校正折射误差的凹曲率的一系列透镜的影响下完成改造。 角膜迅速将其凸曲率重新形成隐形眼镜的凹曲面，使眼睛正视。 允许角膜“硬化”以保持新的正视形状。 在“硬化”发生之后，去除眼睛正视的镜片。

公开(公告)号：US20060280752A1

公开(公告)日：2006-12-14

申请号：US11039578

申请日：2005-01-19

申请人： Lbachir BenMohamed ,  Anthony Nesburn

发明人： Lbachir BenMohamed ,  Anthony Nesburn

IPC分类号： A61K39/245 ,  G06F19/00

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/525 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/55566 ,  A61K2039/57 ,  C12N2710/16622 ,  C12N2710/16634

摘要： Described herein are peptide epitopes effective in the treatment of herpes simplex virus (HSV), as well as vaccines and other therapeutic compositions including the same. In various embodiments, the compositions of the present invention may include a pharmaceutically acceptable adjuvant to enhance the delivery and/or pharmacological efficacy of the epitope. Also described are methods for treating and preventing HSV with the aforementioned epitopes, such as by administering a vaccine including the same. Other methods describe the use of the TEPITOPE algorithm to identify epitopes that may be useful in the treatment of HSV and related or unrelated disease conditions.

摘要翻译： 本文描述了有效治疗单纯疱疹病毒（HSV）的肽表位，以及疫苗和包括其的其它治疗组合物。 在各种实施方案中，本发明的组合物可以包括药学上可接受的佐剂以增强表位的递送和/或药理功效。 还描述了用上述表位治疗和预防HSV的方法，例如通过施用包含其的疫苗。 其他方法描述了使用TEPITOPE算法来鉴定可用于治疗HSV和相关或不相关疾病状况的表位。